Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.

De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, De Man K, Delrue L, Lambert B, Ost P.

Eur Urol. 2018 Nov 28. pii: S0302-2838(18)30839-X. doi: 10.1016/j.eururo.2018.10.044. [Epub ahead of print]

PMID:
30503072
2.

Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.

Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P.

Eur Urol Focus. 2018 Mar;4(2):288-293. doi: 10.1016/j.euf.2015.12.004. Epub 2015 Dec 24.

PMID:
30205893
3.

Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.

Tran S, Jorcano S, Falco T, Lamanna G, Miralbell R, Zilli T.

Am J Clin Oncol. 2018 Oct;41(10):960-962. doi: 10.1097/COC.0000000000000419.

PMID:
29315174
4.

Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.

Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, Kwon E, Karnes RJ.

Eur Urol Focus. 2016 Dec;2(5):522-531. doi: 10.1016/j.euf.2016.01.008. Epub 2016 Feb 10.

PMID:
28723518
5.

Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.

Linxweiler J, Saar M, Al-Kailani Z, Janssen M, Ezziddin S, Stöckle M, Siemer S, Ohlmann CH.

Surg Oncol. 2018 Jun;27(2):138-145. doi: 10.1016/j.suronc.2018.02.010. Epub 2018 Feb 24.

PMID:
29937163
6.

Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, Zelefsky MJ.

Eur Urol. 2017 Jan;71(1):37-43. doi: 10.1016/j.eururo.2016.07.043. Epub 2016 Aug 11.

7.

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A.

Eur Urol. 2019 Jan;75(1):176-183. doi: 10.1016/j.eururo.2018.09.009. Epub 2018 Oct 6.

PMID:
30301694
8.

Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.

Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K.

Eur Urol. 2015 May;67(5):839-49. doi: 10.1016/j.eururo.2014.03.019. Epub 2014 Mar 26. Review.

PMID:
24698524
9.

The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.

Porres D, Pfister D, Thissen A, Kuru TH, Zugor V, Buettner R, Knuechel R, Verburg FA, Heidenreich A.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):85-92. doi: 10.1038/pcan.2016.54. Epub 2016 Nov 8.

PMID:
27824042
10.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
11.

Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.

De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, Villeirs G, De Vos F, De Man K, Decaestecker K, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, Duthoy W, Ost P.

BJU Int. 2017 Dec;120(6):815-821. doi: 10.1111/bju.13938. Epub 2017 Jul 16.

12.

Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients.

Herlemann A, Kretschmer A, Buchner A, Karl A, Tritschler S, El-Malazi L, Fendler WP, Wenter V, Ilhan H, Bartenstein P, Stief CG, Gratzke C.

Oncotarget. 2017 Sep 21;8(48):84180-84192. doi: 10.18632/oncotarget.21118. eCollection 2017 Oct 13.

13.

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F.

Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060. Epub 2011 Aug 3.

PMID:
21840116
14.

Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer.

Montorsi F, Gandaglia G, Fossati N, Suardi N, Pultrone C, De Groote R, Dovey Z, Umari P, Gallina A, Briganti A, Mottrie A.

Eur Urol. 2017 Sep;72(3):432-438. doi: 10.1016/j.eururo.2016.08.051. Epub 2016 Sep 3.

PMID:
27600589
15.

Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.

Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Mollenhauer M, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R.

Eur Urol. 2014 Aug;66(2):222-9. doi: 10.1016/j.eururo.2013.02.007. Epub 2013 Feb 18.

PMID:
23465520
16.

PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases.

Rischke HC, Eiberger AK, Volegova-Neher N, Henne K, Krauss T, Grosu AL, Jilg CA.

Adv Med Sci. 2016 Sep;61(2):212-218. doi: 10.1016/j.advms.2016.01.003. Epub 2016 Feb 3.

PMID:
26895459
17.

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.

Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.

PMID:
24571959
18.

Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.

Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R, Ost P, Briganti A; EAU-YAU Prostate Cancer Working Group.

Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30836-4. doi: 10.1016/j.eururo.2018.10.041. [Epub ahead of print] Review.

PMID:
30391078
19.

Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?

Sivaraman A, Benfante N, Touijer K, Coleman J, Scardino P, Laudone V, Eastham J.

Investig Clin Urol. 2018 Mar;59(2):83-90. doi: 10.4111/icu.2018.59.2.83. Epub 2018 Feb 22.

20.

Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.

Hiester A, Nini A, Niegisch G, Arsov C, Hautzel H, Antke C, Schimmöller L, Albers P, Rabenalt R.

World J Urol. 2019 Jan 14. doi: 10.1007/s00345-019-02633-w. [Epub ahead of print]

PMID:
30643974

Supplemental Content

Support Center